Evaluation of clinical efficacy of homologous Lumpy Skin Disease vaccine against challenge with Iran's circulating virus

Subject Areas : Veterinary Clinical Pathology

Amir Javadi ¹ (Resident of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.)
Samad Lotfollahzadeh ² (Associate Professor, Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.)
Gholamreza Abdollahpour ³ (Professor, Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.)
Arash Ghalyanchilangeroudi ⁴ (Associate Professor, Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.)
Sirous Sadeghian Chaleshtori ⁵ (Assistant Professor, Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.)

Received: 2022-12-25 Accepted : 2023-06-05 Published : 2023-07-23

Keywords: challenge, Vaccine, Clinical evaluation, Lumpy skin disease,

Abstract :

Lumpy skin disease is a viral disease of cattle and buffaloes which causes skin nodules in susceptible animals. Implementation of mass vaccination is the most effective way for LSD control in endemic countries. LSD vaccine that was used in the current study is a domestically produced vaccine containing live attenuated Neethling strain. In this clinical trial, 11 male calves aged 6 to 9 months with an approximate weight of 150 to 250 kg and without antibodies against LSDV were used. The calves were divided into three groups: the first group consisted of two animals that were injected with ten times the vaccine dose, the second group comprised of four calves that were injected with one dose of vaccine and the third group consisted of five calves that received the vaccine diluent and assigned as control. On the 21st day after vaccination, the calves were challenged with a pathogenic strain of LSD virus through simultaneous intravenous and intradermal inoculation. All 11 calves were examined clinically daily for 14 days after the challenge and all clinical signs were recorded. None of the vaccinated animals (ten times the dose and one dose) showed any clinical signs of LSD including cutaneous nodules and fever within 14 days after challenge, while all the animals in the control group (non-vaccinated) showed clinical signs of LSD including cutaneous nodules. Therefore, the vaccine used in the present study was effective in protecting against wild LSD virus.

References:

 

• Abutarbush, S.M., Hananeh, W.M., Ramadan, W., Al Sheyab, O.M., Alnajjar, A.R., Al Zoubi, I.G., et al. (2016). Adverse reactions to field vaccination against lumpy skin disease in ordan. Transboundary and Emerging Diseases, 63(2): e213-e219.


• Ayelet, G., Abate, Y., Sisay, T., Nigussie, H., Gelaye, E., Jemberie, S., et al. (2013). Lumpy skin disease: preliminary vaccine efficacy assessment and overview on outbreak impact in dairy cattle at Debre Zeit, central Ethiopia. Antiviral Research, 98(2): 261-265.


• Arjomandi, N., Haji Hajikolaei, M.R., Seyfi Abad Shapouri, M.R. and Dagheri, M. (2015). Comparison of commercial ELISA kit with serum neutralization (SN) in diagnosis of BHV-1 infections in water buffalo (Buballous buballis). Journal of Veterinary Clinical Pathology, 9(35): 219-229. [In Persian]


• Ben-Gera, J., Klement, E., Khinich, E., Stram, Y. and Shpigel, N. (2015). Comparison of the efficacy of Neethling lumpy skin disease virus and x10RM65 sheep-pox live attenuated vaccines for the prevention of lumpy skin disease–The results of a randomized controlled field study. Vaccine, 33(38): 4837-4842.


• Carn, V. and Kitching, R. (1995). The clinical response of cattle experimentally infected with lumpy skin disease (Neethling) virus. Archives of Virology, 140(3): 503-513.


• Elschner, M. C., Laroucau, K., Singha, H., Tripathi, B. N., Saqib, M., Gardner, I., et al. (2019). Evaluation of the comparative accuracy of the complement fixation test, Western blot and five enzyme-linked immunosorbent assays for serodiagnosis of glanders. PLoS One, 14(4): e0214963.


• Food and Agriculture Organization, Empress360. (2017). Lumpy skin disease special issue. Empress360(47/2017). Retrieved from [e-mail]


• Gari, G., Abie, G., Gizaw, D., Wubete, A., Kidane, M., Asgedom, H., et al. (2015). Evaluation of the safety, immunogenicity and efficacy of three capripoxvirus vaccine strains against lumpy skin disease virus. Vaccine, 33(28): 3256-3261.


• Gubbins, S., Stegeman, A., Klement, E., Pite, L., Broglia, A. and Abrahantes, J.C. (2020). Inferences about the transmission of lumpy skin disease virus between herds from outbreaks in Albania in 2016. Preventive Veterinary Medicine, 181: 104602


• Haegeman, A., De Leeuw, I., Mostin, L., Campe, W.V., Aerts, L., Venter, E., et al. (2021). Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines. Vaccines, 9(5): 473.


• Hamdi, J., Bamouh, Z., Jazouli, M., Boumart, Z., Tadlaoui, K. O., Fihri, O. F., et al. (2020). Experimental evaluation of the cross-protection between Sheeppox and bovine Lumpy skin vaccines. Scientific Reports, 10(1): 1-9.


• Hamdi, J., Boumart, Z., Daouam, S., El Arkam, A., Bamouh, Z., Jazouli, M., et al. (2020). Development and Evaluation of an Inactivated Lumpy Skin Disease Vaccine for Cattle. Veterinary Microbiology, 245, 108689. doi:https://doi.org/10.1016/j.vetmic.2020.108689.


• Hedayati, Z., Varshovi, H.R., Mohammadi, A. and Tabatabaei, M. (2021). Molecular characterization of lumpy skin disease virus in Iran (2014–2018). Archives of Virology, 1-5.


• Katsoulos, P.D., Chaintoutis, S., Dovas, C., Polizopoulou, Z., Brellou, G., Agianniotaki, E., et al. (2018). Investigation on the incidence of adverse reactions, viraemia and haematological changes following field immunization of cattle using a live attenuated vaccine against lumpy skin disease. Transboundary and Emerging Diseases, 65(1): 174-85.


• Klement, E., Broglia, A., Antoniou, S.E., Tsiamadis, V., Plevraki, E., Petrović, T., et al. (2020) Neethling vaccine proved highly effective in controlling lumpy skin disease epidemics in the Balkans. Preventive Veterinary Medicine, 181: 104595.


• Mikhael, C.A, Nakhla, O.E. and Mohamed, N.A. (2017). Study on the capability of a dual capripox vaccine in protection of cattle against LSD infection. Journal of Veterinary Medical Research, 24(1): 61-70.


• Mathijs, E., Vandenbussche, F., Haegeman, A., King, A., Nthangeni, B., Potgieter, et al. (2016). Complete genome sequences of the Neethling-like lumpy skin disease virus strains obtained directly from three commercial live attenuated vaccines. Genome Announcements, 4(6): e01255-01216.


• Mercier, A., Arsevska, E., Bournez, L., Bronner, A., Calavas, D., Cauchard, J., et al. (2018). Spread rate of lumpy skin disease in the Balkans, 2015–2016. Transboundary and Emerging Diseases, 65(1): 240-243.


• Nadalian, M.Gh., Tadjbakhsh, H., Mokhber Dezfouli, M.R. and Akbarein, H. (2017). A review of the most important Zooneses with a special vision towards emerging and re-emerging diseases and its status in Iran Part (1): Bacterail zoonoses. Journal of Veterinary Clinical Pathology, 11(43): 197-223. [In Persian]


• Ngichabe, C., Wamwayi, H., Barrett, T., Ndungu, E., Black, D. and Bostock, C. (1997). Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle. Epidemiology & Infection, 118(1): 63-70.


• Office International des Epizooties (OIE). (2021). OIE Terrestrial Manual, Chapter 3.4.12. Lumpy Skin Disease.


• Sadeghian- Chaleshtori, S., Sharifzadeh, A., Ragh, J., Tavanaeimanesh, H. and Ahmadi, A. (2018). Occurrence of dermatophytosis in different age groups in a dairy farm around Tehran. Journal of Veterinary Clinical Pathology, 11(44): 349-356. [In Persian]


• Tageldin, M.H., Wallace, D.B., Gerdes, G.H., Putterill, J.F., Greyling, R.R., Phosiwa, M.N., et al. (2014). Lumpy skin disease of cattle: an emerging problem in the Sultanate of Oman. Tropical Animal Health and Production, 46(1): 241-24.


• Tuppurainen, E.S.M., Antoniou, S.E., Tsiamadis, E., Topkaridou, M., Labus, T., Debeljak, Z., et al. (2020). Field observations and experiences gained from the implementation of control measures against lumpy skin disease in South-East Europe between 2015 and 2017. Preventive Veterinary Medicine,181: 104600.


• Tuppurainen, E. and Oura, C. (2012). lumpy skin disease: an emerging threat to Europe, the Middle East and Asia. Transboundary and Emerging Diseases, 59(1): 40-48.


• Tuppurainen, E., Venter, E.H., Shisler, J., Gari, G., Mekonnen, G., Juleff, N., et al. (2017). Capripoxvirus diseases: current status and opportunities for control. Transboundary and Emerging Diseases, 64(3), 729-745.


• Tuppurainen, E.S., Pearson, C.R., Bachanek-Bankowska, K., Knowles, N.J., Amareen, S., Frost, L., et al. (2014). Characterization of sheep pox virus vaccine for cattle against lumpy skin disease virus. Antiviral Research, 109: 1-6.